Recently, a study was conducted analyzing 29 men who had been diagnosed with idiopathic osteoporosis, ranging from 27-62 years of age. Each man was placed on Human Growth Hormone replacement therapy. Over the course of the treatment, each man’s bone turnover, bone mineral content, bone size, and bone mineral density were all extensively examined.
The patients were randomly split into two treatment groups, group A and group B. Group A was the continuous treatment group, consisting of 14 members, given daily injections of .4mg of growth hormone. Group B, consisting of 15 members, was given .8 mg of growth hormone for 14 days, every 3 months. Groups A and B were treated for 24 months, with a 12 month follow-up, and took 500mg of calcium and 400 U of vitamin D3 daily for the 36 months.
Body composition, bone mineral density, and bone mineral content were indicated by x-ray and dual energy, every 6 months. After 24 months, group A participants experienced a 4.1% increase in bone mineral density in the lumbar spine, and a 2.6% increase in total body. Group B experienced a 2.7% increase in total body bone density. In both treatment groups, bone mineral content of total and lean body mass increased while fat mass decreased.
The study proved that after 36 months, the bone mineral content and bone mineral density continued to increase in the lumbar spine and total body. Conclusively, a 2-year continuous or intermittent HGH treatment in men with idiopathic osteoporosis can enjoy an increase in bone mineral density and bone mineral content for up to one year following treatment.
